Connection
Stanley Szefler to Nitric Oxide
This is a "connection" page, showing publications Stanley Szefler has written about Nitric Oxide.
|
|
Connection Strength |
|
|
|
|
|
2.210 |
|
|
|
-
Spahn JD, Malka J, Szefler SJ. Current application of exhaled nitric oxide in clinical practice. J Allergy Clin Immunol. 2016 11; 138(5):1296-1298.
Score: 0.382
-
Szefler SJ. Personalised medicine for asthma management in pregnancy. Lancet. 2011 Sep 10; 378(9795):963-4.
Score: 0.269
-
Szefler SJ, Mitchell H, Sorkness CA, Gergen PJ, O'Connor GT, Morgan WJ, Kattan M, Pongracic JA, Teach SJ, Bloomberg GR, Eggleston PA, Gruchalla RS, Kercsmar CM, Liu AH, Wildfire JJ, Curry MD, Busse WW. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet. 2008 Sep 20; 372(9643):1065-72.
Score: 0.219
-
Silkoff PE, Carlson M, Bourke T, Katial R, Ogren E, Szefler SJ. The Aerocrine exhaled nitric oxide monitoring system NIOX is cleared by the US Food and Drug Administration for monitoring therapy in asthma. J Allergy Clin Immunol. 2004 Nov; 114(5):1241-56.
Score: 0.167
-
Wang K, Verbakel JY, Oke J, Fleming-Nouri A, Harada N, Atsuta R, Fujisawa T, Kawayama T, Inoue H, Lazarus S, Szefler S, Martinez FD, Shaw D, Pavord ID, Thomas M. Using fractional exhaled nitric oxide to guide step-down treatment decisions in asthma: practical considerations. Eur Respir J. 2020 08; 56(2).
Score: 0.125
-
Wang K, Verbakel JY, Oke J, Fleming-Nouri A, Brewin J, Roberts N, Harada N, Atsuta R, Takahashi K, Mori K, Fujisawa T, Shirai T, Kawayama T, Inoue H, Lazarus S, Szefler S, Martinez F, Shaw D, Pavord ID, Thomas M. Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis. Eur Respir J. 2020 05; 55(5).
Score: 0.123
-
Fielding SS, Pijnenburg M, de Jongste J, Pike K, Roberts G, Petsky H, Chang AB, Fritsch M, Frischer T, Szefler SJ, Gergen P, Vermeulen F, Vael R, Turner SS. Does treatment guided by exhaled nitric oxide fraction improve outcomes in subgroups of children with asthma? Eur Respir J. 2020 05; 55(5).
Score: 0.123
-
Fielding S, Pijnenburg M, de Jongste J, Pike K, Roberts G, Petsky H, Chang AB, Fritsch M, Frischer T, Szefler S, Gergen P, Vermeulen F, Vael R, Turner S. What is a clinically meaningful change in exhaled nitric oxide for children with asthma? Pediatr Pulmonol. 2020 03; 55(3):599-606.
Score: 0.120
-
Szefler SJ, Chipps B. Challenges in the treatment of asthma in children and adolescents. Ann Allergy Asthma Immunol. 2018 04; 120(4):382-388.
Score: 0.106
-
Teach SJ, Gergen PJ, Szefler SJ, Mitchell HE, Calatroni A, Wildfire J, Bloomberg GR, Kercsmar CM, Liu AH, Makhija MM, Matsui E, Morgan W, O'Connor G, Busse WW. Seasonal risk factors for asthma exacerbations among inner-city children. J Allergy Clin Immunol. 2015 Jun; 135(6):1465-73.e5.
Score: 0.086
-
Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, Hunt JF, Kita H, Liu AH, Panettieri RA, Schleimer RP, Minnicozzi M. Asthma outcomes: biomarkers. J Allergy Clin Immunol. 2012 Mar; 129(3 Suppl):S9-23.
Score: 0.070
-
Rabinovitch N, Graber NJ, Chinchilli VM, Sorkness CA, Zeiger RS, Strunk RC, Bacharier LB, Martinez FD, Szefler SJ. Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma. J Allergy Clin Immunol. 2010 Sep; 126(3):545-51.e1-4.
Score: 0.063
-
Szefler SJ. Individualizing asthma therapy: application of biomarkers. J Asthma. 2008; 45 Suppl 1:29-31.
Score: 0.052
-
Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, Zeiger RS, Larsen G, Spahn JD, Bacharier LB, Bloomberg GR, Guilbert TW, Heldt G, Morgan WJ, Moss MH, Sorkness CA, Taussig LM. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005 Feb; 115(2):233-42.
Score: 0.043
-
Covar RA, Spahn JD, Martin RJ, Silkoff PE, Sundstrom DA, Murphy J, Szefler SJ. Safety and application of induced sputum analysis in childhood asthma. J Allergy Clin Immunol. 2004 Sep; 114(3):575-82.
Score: 0.041
-
Strunk RC, Szefler SJ, Phillips BR, Zeiger RS, Chinchilli VM, Larsen G, Hodgdon K, Morgan W, Sorkness CA, Lemanske RF. Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol. 2003 Nov; 112(5):883-92.
Score: 0.039
-
Covar RA, Szefler SJ, Martin RJ, Sundstrom DA, Silkoff PE, Murphy J, Young DA, Spahn JD. Relations between exhaled nitric oxide and measures of disease activity among children with mild-to-moderate asthma. J Pediatr. 2003 May; 142(5):469-75.
Score: 0.038
-
Fielding S, Pijnenburg M, de Jongste JC, Pike KC, Roberts G, Petsky H, Chang AB, Fritsch M, Frischer T, Szefler S, Gergen P, Vermeulen F, Vael R, Turner S. Change in FEV1 and Feno Measurements as Predictors of Future Asthma Outcomes in Children. Chest. 2019 02; 155(2):331-341.
Score: 0.028
-
Lanz MJ, Leung DY, McCormick DR, Harbeck R, Szefler SJ, White CW. Comparison of exhaled nitric oxide, serum eosinophilic cationic protein, and soluble interleukin-2 receptor in exacerbations of pediatric asthma. Pediatr Pulmonol. 1997 Nov; 24(5):305-11.
Score: 0.026
-
Meltzer LJ, Faino A, Szefler SJ, Strand M, Gelfand EW, Beebe DW. Experimentally manipulated sleep duration in adolescents with asthma: Feasibility and preliminary findings. Pediatr Pulmonol. 2015 Dec; 50(12):1360-7.
Score: 0.022
-
Calhoun WJ, Ameredes BT, King TS, Icitovic N, Bleecker ER, Castro M, Cherniack RM, Chinchilli VM, Craig T, Denlinger L, DiMango EA, Engle LL, Fahy JV, Grant JA, Israel E, Jarjour N, Kazani SD, Kraft M, Kunselman SJ, Lazarus SC, Lemanske RF, Lugogo N, Martin RJ, Meyers DA, Moore WC, Pascual R, Peters SP, Ramsdell J, Sorkness CA, Sutherland ER, Szefler SJ, Wasserman SI, Walter MJ, Wechsler ME, Boushey HA. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA. 2012 Sep 12; 308(10):987-97.
Score: 0.018
-
Gruchalla RS, Sampson HA, Matsui E, David G, Gergen PJ, Calatroni A, Brown M, Liu AH, Bloomberg GR, Chmiel JF, Kumar R, Lamm C, Smartt E, Sorkness CA, Steinbach SF, Stone KD, Szefler SJ, Busse WW. Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: role of predictors in the setting of high adherence. J Allergy Clin Immunol. 2009 Aug; 124(2):213-21, 221.e1.
Score: 0.015
-
Knuffman JE, Sorkness CA, Lemanske RF, Mauger DT, Boehmer SJ, Martinez FD, Bacharier LB, Strunk RC, Szefler SJ, Zeiger RS, Taussig LM. Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. J Allergy Clin Immunol. 2009 Feb; 123(2):411-6.
Score: 0.014
-
Zeiger RS, Szefler SJ, Phillips BR, Schatz M, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, Larsen G, Spahn JD, Bacharier LB, Bloomberg GR, Guilbert TW, Heldt G, Morgan WJ, Moss MH, Sorkness CA, Taussig LM. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol. 2006 Jan; 117(1):45-52.
Score: 0.011
-
Deykin A, Lazarus SC, Fahy JV, Wechsler ME, Boushey HA, Chinchilli VM, Craig TJ, Dimango E, Kraft M, Leone F, Lemanske RF, Martin RJ, Pesola GR, Peters SP, Sorkness CA, Szefler SJ, Israel E. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol. 2005 Apr; 115(4):720-7.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|